CryoPort/$CYRX

1D1W1MYTD1Y5YMAX

About CryoPort

CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
Ticker
$CYRX
Sector
Health
Primary listing
NASDAQ
Employees
688
Headquarters
Brentwood, United States
Website
www.cryoportinc.com

CryoPort Metrics

BasicAdvanced
$836M
-
-$0.91
1.89
-

What the Analysts think about CryoPort

Analyst ratings (Buy, Hold, Sell) for CryoPort stock.
Analyst projections of the future price of CryoPort stock.

Bulls say / Bears say

Cryoport is gaining traction in higher-value services: Q2 revenue rose 8%, Life Sciences Services grew 15% and BioStorage/BioServices grew 25%. Commercial CGT service revenue rose 26%, while the company supported a record 779 clinical trials and 22 approved therapies. (Cryoport, PR Newswire)
The company reached positive adjusted EBITDA of $0.4 million in Q2 and improved first-half operating cash flow by about $17 million year on year. It also reaffirmed 2026 revenue guidance of $192 million to $196 million, supporting the case that recent investments are beginning to create operating leverage. (PR Newswire, The Motley Fool)
Cryoport is broadening its integrated offering beyond transport. IntegriCell won work with Verismo’s two Phase 1 CAR-T programmes, while the new 86,500-square-foot Santa Ana centre creates capacity to combine logistics, cryopreservation, BioServices and biostorage. (PR Newswire, Cryoport Systems)
Cryoport remains loss-making despite the adjusted EBITDA milestone: Q2 operating loss was about $10.0 million, net loss was about $8.3 million and EPS missed consensus by one cent. The improvement therefore still needs to become repeatable cash earnings. (Cryoport, MarketBeat)
Commercial CGT revenue grew only 9% year on year in Q2, slower than the 26% growth in the Life Sciences Services portion of commercial CGT. That leaves Cryoport exposed to uneven therapy launches, clinical funding and regulatory approvals rather than a consistently accelerating demand curve. (Cryoport, Simply Wall St)
The profitability plan still depends on new infrastructure being filled. Management says the first two IntegriCell sites are proofing sites and that industry adoption will take time, while new facilities in France and California add fixed costs before their full revenue contribution is clear. (The Motley Fool, Cryoport Systems)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.

CryoPort Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

CryoPort Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

CryoPort News

AllArticlesVideos

CryoPort Q2 Earnings Call Highlights

MarketBeat1 month ago

Funds containing CryoPort

AllGBPEUR
Funds
Fund name
Fund size
$CYRX weighting
Xtrackers S&P 500 Swap£XSPX
£3.1B0.03%
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.03%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.